The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD

This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Inclusion Criteria:

• COPD diagnosis
• FEV1/FVC<70%
• FEV1 50-80% predicted
• Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL
• RV > 120% predicted
• DLCO < 80%
• smokers and nonsmokers
• Lower age limit 45 years

Exclusion Criteria:

• Asthma
• Other chronic airway or parenchymal lung disease
• Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)
• Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks
• Use of theophylline, leukotriene modifiers within 12 weeks
• Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)